Ginkgo Bioworks Q2 Revenue Halves to $20M, Cash Runway Tightens as $47M Gets Locked Up

summarizeSummary

Ginkgo Bioworks reported a 49% revenue drop in Q2 2026 to $20.2M, with $47M in cash now restricted, tightening its runway. The company raised $16.5M via ATM share sales and says it has enough cash for at least 12 months.

check_boxKey Events · Earnings and Guidance · DNA

• Revenue Plunges 49%

  Q2 2026 revenue fell to $20.2 million from $39.1 million a year ago, driven by reduced scope from a large agriculture customer and fewer pharma/biotech programs.

• Cash Runway Under Pressure

  Cash, equivalents, and marketable securities totaled $302.2 million at quarter-end, but $47 million is now restricted for a surety bond until 2029. Management believes this is sufficient for at least 12 months.

• ATM Dilution Continues

  The company sold 1.8 million shares in Q2 for net proceeds of $16.5 million under its at-the-market program, bringing total ATM proceeds to $34.6 million since inception.

• Biosecurity Divestiture Closed

  The sale of the Biosecurity business closed on April 3, 2026, resulting in a $24.5 million non-cash gain on deconsolidation. The business is now reported as discontinued operations.

auto_awesomeAnalysis · DNA · Life Sciences

Ginkgo Bioworks' Q2 2026 results show a 49% revenue decline to $20.2 million, deepening losses and accelerating cash burn. The company's liquidity position is under pressure: $47 million in cash is now restricted to secure a surety bond until 2029, leaving $302 million in total cash and securities. Management says this is enough for at least 12 months, but the runway is shrinking fast. The company also sold 1.8 million shares through its ATM program in Q2, raising $16.5 million, adding to dilution. The Biosecurity divestiture closed, generating a one-time $24.5 million gain but removing a revenue stream. With no clear path to profitability and a declining cash cushion, the survival clock is ticking louder.